NX Development Corp | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
NX Development Corp

BRIEF

published on 06/21/2024 at 15:05, 1 year 5 months ago

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)

Gleolan NX Development Corp. OVA-302 Study FDA Orphan Designation
PRESS RELEASE

published on 06/21/2024 at 15:00, 1 year 5 months ago

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)
NX Development Corp. enrolls first patient in OVA-302 study for cancer management using Gleolan following FDA's Orphan Designation. CEO DeSena and Chairman Kosciessa express excitement for future programs

Gleolan NX Development Corp. OVA-302 Study Cancer Management Flourescence-guided Surgery
BRIEF

published on 03/05/2024 at 23:05, 1 year 8 months ago

NX Development Corp. Awarded Orphan-Drug Designation for Gleolan in Ovarian Cancer Treatment

FDA NX Development Corp Orphan-Drug Designation Gleolan Ovarian Cancer
PRESS RELEASE

published on 03/05/2024 at 23:00, 1 year 8 months ago

NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan(R) in Ovarian and Related Cancers
NX Development Corp. has achieved orphan-drug status from the FDA for Gleolan, aiding in the visualization of ovarian tumors during surgery. The milestone highlights innovation in cancer care and surgery

FDA Cancer Care Gleolan NX Development Corp. Orphan-drug Status

Accesswire

Published on 12/05/2025 at 02:35, 1 hour 54 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 1 hour 59 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 3 hours 29 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 5 hours 24 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 5 hours 29 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 59 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 4 hours 39 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 4 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 8 hours 14 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 9 hours 19 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 10 hours 29 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 10 hours 44 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 10 hours 45 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 21 hours 28 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 10 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE